An announcement from Bio-Rad Laboratories ( ($BIO) ) is now available. On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on ...

Together with Bio-Rad’s existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the most undervalued healthcare stocks. It is a global leader in life science research and clinical diagnostics and advanced its digital PCR ...

Bio-Rad will continue to seek regulatory approvals for additional global markets in the coming months. The CFX Opus Deepwell Dx Real-Time PCR System is the latest addition to the Bio-Rad portfolio of ...

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products ...

Rémi Dangla, CEO of Stilla Technologies, stated, "We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ...

The CFX96 optical reaction module builds on the flexibility of the C1000 thermal cycler, creating a real-time PCR system that can deliver sensitive detection for real-time PCR applications, including ...

“This collaboration advances Bio-Rad’s strategy to establish Droplet Digital PCR as a foundational technology by providing researchers and laboratories with high-value assays across a variety ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of an RT-PCR kit that allows researchers to simultaneously screen samples for Zika (ZIKV), dengue (DENV1, DENV2, DENV3, DENV4 ...

Bio-Rad Laboratories, Inc. | NuProbe USA will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays.

Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024.